^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-24714

    i
    Other names: BGB-24714, BGB24714, BGB 24714
    Associations

    News

    Trials
    Company:
    BeiGene
    Drug class:
    IAP antagonist
    Related drugs:
    Associations

    News

    Trials
    8ms
    BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=229, Recruiting, BeiGene | N=168 --> 229
    Enrollment change • Combination therapy
    |
    carboplatin • paclitaxel • docetaxel • BGB-24714
    1year
    BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=168, Recruiting, BeiGene | Trial completion date: Jul 2027 --> Nov 2026 | Trial primary completion date: Jan 2027 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    carboplatin • paclitaxel • BGB-24714
    over1year
    BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel (AACR 2023)
    BGB-24714 effectively inhibited cIAP1 by inducing its degradation in MDA-MB-231 cells, with an EC50 of 2.5 nM. BGB-24714 also potently antagonized the inhibitory interaction of XIAP with caspase-9 and induced caspase-9 autoactivation in MDA-MB-231 cells, with an EC50 of 23 nM. In a total of 25 breast cancer cell lines treated with TNFα, BGB-24714 potently inhibited the in vitro proliferation of 5 breast cancer cells with EC50 < 100 nM.
    Preclinical • Combination therapy
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP9 (Caspase 9) • XIAP (X-Linked Inhibitor Of Apoptosis)
    |
    paclitaxel • BGB-24714